H.C. Wainwright Sticks to Their Buy Rating for Mersana Therapeutics Inc
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Monday, setting a price target of $13, which is approximately 32.52% above the present share price of $9.81.
Chattopadhyay expects Mersana Therapeutics Inc to post earnings per share (EPS) of -$0.34 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Mersana Therapeutics, with an average price target of $13.
The analysts price targets range from a high of $14 to a low of $12.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $42.00 thousand thousand and a net profit of -$16.6 million. The company's market cap is $578.22 million.
According to TipRanks.com, H.C. Wainwright analyst Debjit Chattopadhyay is a 4-star analyst with an average return of 6.8% and a 43.4% success rate.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
